David B. Kanne

TL;DR: It injection of STING agonists induced profound regression of established tumors in mice and generated substantial systemic immune responses capable of rejecting distant metastases and providing long-lived immunologic memory.

TL;DR: The authors modified the cyclic dinucleotides to strengthen their binding to human STING, increasing their antitumor activity and showed that treatment with STINGVAX caused cancer cells to up-regulate PD-L1, a protein that suppresses the immune response.

TL;DR: Clinical candidate STING agonist ADU-S100 (S100) is used in an IT dosing regimen optimized for adaptive immunity to uncover requirements for a T cell-driven response compatible with checkpoint inhibitors (CPIs), providing fundamental mechanistic insights into STING-induced anti-tumor immunity.

TL;DR: In a murine model of pancreatic cancer, it is shown that combining CT-guided radiotherapy with a novel ligand of murine and human STING could synergize to control local and distant tumors.

TL;DR: Although this relatively new class of adjuvants has to date only been evaluated in mice, newly available CDN-STING cocrystal structures will likely intensify efforts in this field towards further development and evaluation in human trials both in preventive vaccine and immunotherapy settings.